A531 PRIA Fee Category

PRIA 5 Fee Determination Decision Tree:

Antimicrobial Active Ingredient Registration for End Use Product

Below is the fee for your selected Fee Category for Fiscal Years 2025-2026

Action Code	Description	FY'25 - FY'26 Fee	Decision Time (months)
A531	New product; identical or substantially similar in composition and use to a registered product; registered source of active ingredient: selective data citation only for data on product chemistry and/or acute toxicity and/or public health pest efficacy, where applicant does not own all required data and does not have a specific authorization letter from data owner. ⁽²⁾ ⁽³⁾	$2,747	4

Do you plan to request either of the following types of waivers?

Waiver	Pay	Amount
50% waiver	You pay ---->>>>>	$1,374
75% waiver	You pay ---->>>>>	$687

To pay the fee shown above, go to Paying PRIA Application Fees web page and follow the instructions.

How to submit your application directly to EPA.

Action Code Interpretation
An application for registration of an end-use pesticide product that is substantially similar or identical in its uses and/or formulation to products that are currently registered or differ only in ways that would not significantly increase the risk of unreasonable adverse effects. The applicant must identify the similar products for all active ingredients in the proposed product. All applications require the following: A data matrix is required with the application. Product chemistry data (Group A and B) unless the product is identical. In some cases product chemistry data can be satisfied as outlined in PR Notice 98-1. All inert ingredients used in the product must be EPA approved for the proposed use(s), pending approval with the Agency for the applicable uses, or included in an inert petition submitted within the package for the applicable uses. Each application for a new inert approval submitted in this package is subject to its own registration service fee. The source of the active ingredient must be currently registered (licensed) with the Agency. In all cases, the applicant must identify the currently registered similar product for this category. The similar product must be identified on the 8570-1 application form. Acute toxicity, efficacy, public health pest efficacy, and/or child resistant packaging data requirement must be addressed by using: 1) the cite-all method, or 2) selective data citation where the applicant does not own all required data and does not have a specific authorization letter from the data owner. If a review of data other than product chemistry is needed, the application does not fall into this category. The application does not fall into this category if efficacy, acute toxicity, companion animal safety, and/or child resistant packaging data are submitted and must be reviewed to support the application. The application does not fall into this category if it contains a request to waive any of these data. An application that requires review of cited or submitted data other than product chemistry does not belong in this fee category. Substantially similar: Product must have the same active ingredient, in substantially the same proportion, same chemical composition (solid, liquid, granular), and substantially similar inert ingredients as the already registered product. In addition, substantially similar means that the product bears the same use patterns or fewer. Adding to or changing existing use patterns excludes the product from treatment as a substantially similar product. Substantially similar use patterns for public health products are limited to identical organisms on both products. For non-public health products substantially similar use patterns are limited to identical organisms on both products. Deleting use patterns is acceptable. Identical products: Same composition and use patterns as an already registered end-use product. Manufacturing Use Product: A 100% re-package of a manufacturing use product that requires no data submission nor data matrix is covered by this category. Unregistered: The Agency has not issued an EPA Registration Number (license) for the source material. An application for a new end-use product using a source of active ingredient that is not yet registered but has an application pending with the Agency for review, will be considered an application for a new product with an unregistered source of active ingredient. A different pattern of use that significantly changes or increases exposure such as a dosage rate increase or different method of application will result in the application being treated as a new use. The company is required to provide a cited label to support the proposed uses by showing that the use pattern and rates do not exceed currently registered products. The Agency will provide the applicant with a pre-decisional determination 2 weeks prior to the PRIA decision review time due date which specifies any label changes that have to be made in order to grant the requested new product registration. If the label issues cannot be resolved prior to the PRIA decision review time due date, then the Agency will issue to the applicant its regulatory decision with the specific label changes and supporting documentation on or just before the PRIA decision review time due date. At that time the applicant must either (a) agree to all of the label changes and submit a revised label that incorporates all of these label changes; or (b) does not agree with one or more of the label changes and request up to 30 days to reach agreement with the Agency and submit a revised label that incorporates all of the agreed upon label changes, which the Agency has 2 business days to review; or (c) withdraw the application without prejudice.

Action Code Interpretation

An application for registration of an end-use pesticide product that is substantially similar or identical in its uses and/or formulation to products that are currently registered or differ only in ways that would not significantly increase the risk of unreasonable adverse effects. The applicant must identify the similar products for all active ingredients in the proposed product.

All applications require the following:

A data matrix is required with the application.
Product chemistry data (Group A and B) unless the product is identical. In some cases product chemistry data can be satisfied as outlined in PR Notice 98-1.
All inert ingredients used in the product must be EPA approved for the proposed use(s), pending approval with the Agency for the applicable uses, or included in an inert petition submitted within the package for the applicable uses. Each application for a new inert approval submitted in this package is subject to its own registration service fee.
The source of the active ingredient must be currently registered (licensed) with the Agency.
In all cases, the applicant must identify the currently registered similar product for this category. The similar product must be identified on the 8570-1 application form.
Acute toxicity, efficacy, public health pest efficacy, and/or child resistant packaging data requirement must be addressed by using: 1) the cite-all method, or 2) selective data citation where the applicant does not own all required data and does not have a specific authorization letter from the data owner. If a review of data other than product chemistry is needed, the application does not fall into this category.

The application does not fall into this category if efficacy, acute toxicity, companion animal safety, and/or child resistant packaging data are submitted and must be reviewed to support the application. The application does not fall into this category if it contains a request to waive any of these data. An application that requires review of cited or submitted data other than product chemistry does not belong in this fee category.

Substantially similar: Product must have the same active ingredient, in substantially the same proportion, same chemical composition (solid, liquid, granular), and substantially similar inert ingredients as the already registered product. In addition, substantially similar means that the product bears the same use patterns or fewer. Adding to or changing existing use patterns excludes the product from treatment as a substantially similar product. Substantially similar use patterns for public health products are limited to identical organisms on both products. For non-public health products substantially similar use patterns are limited to identical organisms on both products.

Deleting use patterns is acceptable.

Identical products: Same composition and use patterns as an already registered end-use product.

Manufacturing Use Product: A 100% re-package of a manufacturing use product that requires no data submission nor data matrix is covered by this category.

Unregistered: The Agency has not issued an EPA Registration Number (license) for the source material.

An application for a new end-use product using a source of active ingredient that is not yet registered but has an application pending with the Agency for review, will be considered an application for a new product with an unregistered source of active ingredient.

A different pattern of use that significantly changes or increases exposure such as a dosage rate increase or different method of application will result in the application being treated as a new use. The company is required to provide a cited label to support the proposed uses by showing that the use pattern and rates do not exceed currently registered products.

The Agency will provide the applicant with a pre-decisional determination 2 weeks prior to the PRIA decision review time due date which specifies any label changes that have to be made in order to grant the requested new product registration. If the label issues cannot be resolved prior to the PRIA decision review time due date, then the Agency will issue to the applicant its regulatory decision with the specific label changes and supporting documentation on or just before the PRIA decision review time due date. At that time the applicant must either (a) agree to all of the label changes and submit a revised label that incorporates all of these label changes; or (b) does not agree with one or more of the label changes and request up to 30 days to reach agreement with the Agency and submit a revised label that incorporates all of the agreed upon label changes, which the Agency has 2 business days to review; or (c) withdraw the application without prejudice.

Go to the start of the Decision Tree

A531 PRIA Fee Category

PRIA 5 Fee Determination Decision Tree:

Antimicrobial Active Ingredient Registration for End Use Product

Below is the fee for your selected Fee Category for Fiscal Years 2025-2026

PRIA Fees